Background: The rapid advancement of artificial intelligence (AI) in healthcare necessitates comprehensive and standardized reporting guidelines to ensure transparency, reproducibility, and ethical applications in clinical research. Existing reporting standards are limited by their focus on specific study designs. We aimed to develop a comprehensive set of guidelines and a checklist for reporting studies that develop and utilize AI models in healthcare, covering all essential components of AI research regardless of the study design. Methods: Two experts in statistics from the Statistical Round of the Korean Journal of Anesthesiology developed these guidelines and checklist. The key elements essential for AI model reporting were identified and organized into structured sections, including study design, data preparation, model training and evaluation, ethical considerations, and clinical implementation. Iterative reviews and feedback from clinicians and researchers were used to finalize the guidelines and checklist. Results: These guidelines provide a detailed description of each item on the checklist, ensuring comprehensive reporting of AI model research. Full details regarding the AI model specifications and data-handling processes are provided. Conclusions These guidelines and checklist are meant to serve as valuable tools for researchers, addressing key aspects of AI reporting, and thereby supporting the reliability, accountability, and ethical use of AI in healthcare research.

Background: The rapid advancement of artificial intelligence (AI) in healthcare necessitates comprehensive and standardized reporting guidelines to ensure transparency, reproducibility, and ethical applications in clinical research. Existing reporting standards are limited by their focus on specific study designs. We aimed to develop a comprehensive set of guidelines and a checklist for reporting studies that develop and utilize AI models in healthcare, covering all essential components of AI research regardless of the study design. Methods: Two experts in statistics from the Statistical Round of the Korean Journal of Anesthesiology developed these guidelines and checklist. The key elements essential for AI model reporting were identified and organized into structured sections, including study design, data preparation, model training and evaluation, ethical considerations, and clinical implementation. Iterative reviews and feedback from clinicians and researchers were used to finalize the guidelines and checklist. Results: These guidelines provide a detailed description of each item on the checklist, ensuring comprehensive reporting of AI model research. Full details regarding the AI model specifications and data-handling processes are provided. Conclusions These guidelines and checklist are meant to serve as valuable tools for researchers, addressing key aspects of AI reporting, and thereby supporting the reliability, accountability, and ethical use of AI in healthcare research.

Background: The rapid advancement of artificial intelligence (AI) in healthcare necessitates comprehensive and standardized reporting guidelines to ensure transparency, reproducibility, and ethical applications in clinical research. Existing reporting standards are limited by their focus on specific study designs. We aimed to develop a comprehensive set of guidelines and a checklist for reporting studies that develop and utilize AI models in healthcare, covering all essential components of AI research regardless of the study design. Methods: Two experts in statistics from the Statistical Round of the Korean Journal of Anesthesiology developed these guidelines and checklist. The key elements essential for AI model reporting were identified and organized into structured sections, including study design, data preparation, model training and evaluation, ethical considerations, and clinical implementation. Iterative reviews and feedback from clinicians and researchers were used to finalize the guidelines and checklist. Results: These guidelines provide a detailed description of each item on the checklist, ensuring comprehensive reporting of AI model research. Full details regarding the AI model specifications and data-handling processes are provided. Conclusions These guidelines and checklist are meant to serve as valuable tools for researchers, addressing key aspects of AI reporting, and thereby supporting the reliability, accountability, and ethical use of AI in healthcare research.

Background: The rapid advancement of artificial intelligence (AI) in healthcare necessitates comprehensive and standardized reporting guidelines to ensure transparency, reproducibility, and ethical applications in clinical research. Existing reporting standards are limited by their focus on specific study designs. We aimed to develop a comprehensive set of guidelines and a checklist for reporting studies that develop and utilize AI models in healthcare, covering all essential components of AI research regardless of the study design. Methods: Two experts in statistics from the Statistical Round of the Korean Journal of Anesthesiology developed these guidelines and checklist. The key elements essential for AI model reporting were identified and organized into structured sections, including study design, data preparation, model training and evaluation, ethical considerations, and clinical implementation. Iterative reviews and feedback from clinicians and researchers were used to finalize the guidelines and checklist. Results: These guidelines provide a detailed description of each item on the checklist, ensuring comprehensive reporting of AI model research. Full details regarding the AI model specifications and data-handling processes are provided. Conclusions These guidelines and checklist are meant to serve as valuable tools for researchers, addressing key aspects of AI reporting, and thereby supporting the reliability, accountability, and ethical use of AI in healthcare research.

Background: Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined. Methods: This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months. Conclusion This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.

In this paper, we review the use of hypofractionated radiotherapy for gastrointestinal malignancies, focusing on primary and metastatic liver cancer, and recurrent rectal cancer. Technological advancements in radiotherapy have facilitated the direct delivery of high-dose radiation to tumors, while limiting normal tissue exposure, supporting the use of hypofractionation. Hypofractionated radiotherapy is particularly effective for primary and metastatic liver cancer where high-dose irradiation is crucial to achieve effective local control. For recurrent rectal cancer, the use of stereotactic body radiotherapy offers a promising approach for re-irradiation, balancing efficacy and safety in patients who have been administered previous pelvic radiotherapy and in whom salvage surgery is not applicable. Nevertheless, the potential for radiation-induced liver disease and gastrointestinal complications presents challenges when applying hypofractionation to gastrointestinal organs. Given the lack of universal consensus on hypofractionation regimens and the dose constraints for primary and metastatic liver cancer, as well as for recurrent rectal cancer, this review aims to facilitate clinical decision-making by pointing to potential regimens and dose constraints, underpinned by a comprehensive review of existing clinical studies and guidelines.

Hypofractionated radiotherapy (RT) has become a trend in the modern era, as advances in RT techniques, including intensity-modulated RT and image-guided RT, enable the precise and safe delivery of high-dose radiation. Hypofractionated RT offers convenience and can reduce the financial burden on patients by decreasing the number of fractions. Furthermore, hypofractionated RT is potentially more beneficial for tumors with a low α/β ratio compared with conventional fractionation RT. Therefore, hypofractionated RT has been investigated for various primary cancers and has gained status as a standard treatment recommended in the guidelines. In genitourinary (GU) cancer, especially prostate cancer, the efficacy, and safety of various hypofractionated dose schemes have been evaluated in numerous prospective clinical studies, establishing the standard hypofractionated RT regimen. Hypofractionated RT has also been explored for gynecological (GY) cancer, yielding relevant evidence in recent years. In this review, we aimed to summarize the representative evidence and current trends in clinical studies on hypofractionated RT for GU and GY cancers addressing several key questions. In addition, the objective is to offer suggestions for the available dose regimens for hypofractionated RT by reviewing protocols from previous clinical studies.

In this paper, we review the use of hypofractionated radiotherapy for gastrointestinal malignancies, focusing on primary and metastatic liver cancer, and recurrent rectal cancer. Technological advancements in radiotherapy have facilitated the direct delivery of high-dose radiation to tumors, while limiting normal tissue exposure, supporting the use of hypofractionation. Hypofractionated radiotherapy is particularly effective for primary and metastatic liver cancer where high-dose irradiation is crucial to achieve effective local control. For recurrent rectal cancer, the use of stereotactic body radiotherapy offers a promising approach for re-irradiation, balancing efficacy and safety in patients who have been administered previous pelvic radiotherapy and in whom salvage surgery is not applicable. Nevertheless, the potential for radiation-induced liver disease and gastrointestinal complications presents challenges when applying hypofractionation to gastrointestinal organs. Given the lack of universal consensus on hypofractionation regimens and the dose constraints for primary and metastatic liver cancer, as well as for recurrent rectal cancer, this review aims to facilitate clinical decision-making by pointing to potential regimens and dose constraints, underpinned by a comprehensive review of existing clinical studies and guidelines.

Hypofractionated radiotherapy (RT) has become a trend in the modern era, as advances in RT techniques, including intensity-modulated RT and image-guided RT, enable the precise and safe delivery of high-dose radiation. Hypofractionated RT offers convenience and can reduce the financial burden on patients by decreasing the number of fractions. Furthermore, hypofractionated RT is potentially more beneficial for tumors with a low α/β ratio compared with conventional fractionation RT. Therefore, hypofractionated RT has been investigated for various primary cancers and has gained status as a standard treatment recommended in the guidelines. In genitourinary (GU) cancer, especially prostate cancer, the efficacy, and safety of various hypofractionated dose schemes have been evaluated in numerous prospective clinical studies, establishing the standard hypofractionated RT regimen. Hypofractionated RT has also been explored for gynecological (GY) cancer, yielding relevant evidence in recent years. In this review, we aimed to summarize the representative evidence and current trends in clinical studies on hypofractionated RT for GU and GY cancers addressing several key questions. In addition, the objective is to offer suggestions for the available dose regimens for hypofractionated RT by reviewing protocols from previous clinical studies.

In this paper, we review the use of hypofractionated radiotherapy for gastrointestinal malignancies, focusing on primary and metastatic liver cancer, and recurrent rectal cancer. Technological advancements in radiotherapy have facilitated the direct delivery of high-dose radiation to tumors, while limiting normal tissue exposure, supporting the use of hypofractionation. Hypofractionated radiotherapy is particularly effective for primary and metastatic liver cancer where high-dose irradiation is crucial to achieve effective local control. For recurrent rectal cancer, the use of stereotactic body radiotherapy offers a promising approach for re-irradiation, balancing efficacy and safety in patients who have been administered previous pelvic radiotherapy and in whom salvage surgery is not applicable. Nevertheless, the potential for radiation-induced liver disease and gastrointestinal complications presents challenges when applying hypofractionation to gastrointestinal organs. Given the lack of universal consensus on hypofractionation regimens and the dose constraints for primary and metastatic liver cancer, as well as for recurrent rectal cancer, this review aims to facilitate clinical decision-making by pointing to potential regimens and dose constraints, underpinned by a comprehensive review of existing clinical studies and guidelines.